RTS,S malaria vaccine development: progress and considerations for postapproval introduction

Abstract

Though the burden of malaria has decreased in the last decade in some sub-Saharan African countries, it is still high in others, and there is no malaria vaccine in use. The development of malaria vaccines in combination with current control programs could be effective in reducing the malaria burden. In this paper, we review and discuss the progress made in the RTS,S malaria vaccine development and considerations for its postapproval process. We conclude that the development of malaria vaccines has been a long process confronted with challenges of funding, difficulty in identifying malaria antigens that correlate with protection, and development of adjuvant systems among others. The scientific approval of the vaccine by the European Medicines Agency in July 2015 and subsequent recommendations for pilot implementation studies by the World Health Organization made history as the first human parasite vaccine. It is also a major public health achievement as the vaccine has the potential to prevent thousands of malaria cases. However, there are implementation challenges such as cold chain systems, community acceptance, and monitoring of adverse events post-licensure that need to be carefully addressed.

Willingness to accept malaria vaccine among caregivers of under-5 children in Southwest Ethiopia: a community based cross-sectional study

“…In response to the drawbacks of current malaria control strategies, the United Nations Development Programme, World Bank and WHO-Tropical Diseases Research programme, in collaboration with pharmaceutical industry experts have explored other novel approaches to malaria control, one of which is the use of vaccinations [ 15 ]. Vaccination is a public health strategy that is very effective in disease control and has successfully eradicated some infectious diseases, such as smallpox and is currently very promising in eradicating poliomyelitis [ 16 ].…”

A cutting-edge immunoinformatics approach for design of multi-epitope oral vaccine against dreadful human malaria

“…According to VIOLIN database (accessed on June 26, 2019), total 16 vaccines available so far for against P. falciparum from different life-cycle stages, but they have not succeed to get approval from FDA, USA for world-wide marketing [60]. The RTS,S/AS01 is the only world's first European Medicines Agency (EMA) approved malaria vaccine with partial protection in young children (36.3%) for use to only Sub-Saharan African region along with severe adverse effect (24.2%-28.4%) and incurable adverse effect (1.5%-2.5%) [61,62]. In addition, the efficacy was further declined to almost zero after 4th year and negative in 5th year [63].…”

Malaria Vaccine Development: Previous Success, Current Status and Future Prospects

“…According to Asante et al (2016), there is broad agreement that development of new and effective vaccine products cannot proceed without a detailed understanding of the immune correlates of protection. This is imperative in the design and evaluation of vaccine efficacy.…”